NCT07458061

Kamuvudine-9 (K9) in Diabetic Macular Edema

Randomized Trial of Kamuvudine-9 (K9) in DME

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Dr. Bryan Strelow · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral placebo

Conditions

• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	Placebo Tablet: BID	Placebo tablets BID
DRUG	Kamuvudine K9	Kamuvudine K9

Timeline

• Start date: 2026-02-01
• Primary completion: 2026-06-01
• Completion: 2026-08-01
• First posted: 2026-03-09
• Last updated: 2026-03-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study